GUTS
Fractyl Health, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$0.78-3.60%
Price as of Jul 20, 2026
GUTS financials
Fractyl Health, Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $93.0K | $120.0K | $0.00 |
| Cost of revenue | $0.00 | $50.0K | $77.0K | $452.0K |
| Gross profit | $0.00 | $43.0K | $43.0K | -$452.0K |
| Operating expenses | $96.8M | $93.6M | $50.9M | $48.9M |
| Operating income | -$96.8M | -$93.5M | -$50.8M | -$49.4M |
| Net income | -$141.0M | -$68.7M | -$77.1M | -$46.5M |
| EBITDA | -$139.8M | -$68.0M | -$76.8M | -$46.0M |
| Basic EPS | $-1.86 | $-1.62 | $-1.98 | $-1.34 |
| Diluted EPS | $-1.86 | $-1.62 | $-1.98 | $-1.34 |
| Balance sheet | ||||
| Cash & equivalents | $81.5M | $67.5M | $33.5M | $49.3M |
| Total assets | $121.4M | $108.1M | $76.2M | $61.0M |
| Total liabilities | $111.9M | $79.7M | $401.3M | $313.3M |
| Stockholders’ equity | $9.5M | $28.4M | -$325.1M | -$252.3M |
| Total debt | $61.6M | $62.5M | $373.7M | $306.8M |
| Net debt | -$19.9M | -$5.0M | $340.2M | $257.5M |
| Cash flow | ||||
| Operating cash flow | -$90.3M | -$65.5M | -$42.8M | -$46.2M |
| Capital expenditure | -$557.0K | -$1.8M | -$359.0K | -$56.0K |
| Free cash flow | -$90.9M | -$67.3M | -$43.2M | -$46.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |